A Phase 4 interventional study of PDS Implant filled with 100 mg/mL Ranibizumab and Ranibizumab in Proliferative Diabetic Retinopathy, Diabetic Retinopathy and Diabetes, sponsored by Southeast Retina Center, Georgia. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Southeast Retina Center, Georgia · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing ranibizumab in Diabetic Retinopathy — 2 open to participants now, 2 under way, 1 of them phase 3. Ranibizumab · Diabetic Retinopathy.
Among the 34 studies testing ranibizumab in Diabetic Retinopathy, this one is the 26th largest by planned enrollment, is the only one that started in 2026, is one of 10 in phase 4, and was the 33rd registered.
783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.
Browse Diabetic Retinopathy studies →2 of the 34 studies testing ranibizumab in Diabetic Retinopathy are open now, in 2 countries. Recruiting first, the newest first:
Affiliated Hospital of Nantong University · Sites in China
Ages 18–80
By country, each count listing its studies:
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 9 · Phase 4 10
First in 2006; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 80 across 484 interventional studies indexed under Diabetic Retinopathy.
Median enrollment 57 across the 34 interventional studies. Of the 23 that completed or were terminated, 9 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 34 have an industry lead sponsor. The 10 most frequent:
Southeast Retina Center, Georgia is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Southeast Retina Center, Georgia has 1 study filed under Diabetic Retinopathy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing ranibizumab in Diabetic Retinopathy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In prolifertive diabetic retinopathy (PDR) eyes with bleeding known as vitreous hemorrhage (VH) requiring a surgical procedure to remove the vitreous, called a vitrectomy, we will determine if the benefit and safety of adding a small implant that will be filled with medication called Susvimo is better with limited laser treatment.
In PDR eyes with vitreous hemorrhage (VH) requiring vitrectomy, we propose to determine the safety and efficacy of adding the port delivery system (PDS) ranibizumab implant while omitting standard PRP endolaser but with the option to retain limited peripheral endolaser PRP based on surgeon discretion.
Inclusion Criteria:
Patients must meet the following general inclusion criteria (for study entry):
Women must remain abstinent or use contraceptive methods with a failure rate of \< 1% per year during the treatment period and for at least 28 days after the last intravitreal injection of ranibizumab or 1 year after the last implant refill exchange of ranibizumab.
A woman is considered to be of childbearing potential if she is post-menarchal, has not reached a state ( Greater than or equal to, 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). The definition of childbearing potential may be adapted for alignment with local guidelines or requirements.
Examples of contraceptive methods with a failure rate of \< 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.
The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
4.1.1.2 Ocular Inclusion Criteria
Exclusion Criteria:
1.1.1 Exclusion Criteria
1.1.1.1 Prior Ocular Treatment
Patients who meet any of the following prior ocular treatment exclusion criteria will be excluded from study entry:
Study Eye
1.1.1.2 VH Characteristics
Patients who meet any of the following exclusion criteria related to VH characteristics will be excluded from study entry:
Study Eye
1.1.1.3 Concurrent Ocular Conditions
Patients who meet any of the following exclusion criteria related to concurrent ocular conditions will be excluded from study entry:
Study Eye
1.1.1.4 Concurrent Systemic Conditions
Patients who meet any of the following exclusion criteria related to concurrent systemic conditions will be excluded from study entry:
1.2 METHOD OF TREATMENT ASSIGNMENT Open label with PDS ranibizumab (100mg/ml) with implant/exchange injection q6mos and q9mos for eyes with and without DME, respectively. Estimated 20 eyes enrolled and 30 eyes screened at rate of accrual of 20 eyes at 1 year and follow-up 1 year (2 years total duration of study)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-labeled, non-randomized, single-arm surgical case series will enroll 20 PDR eyes with VH requiring (determined by investigator prior to baseline/screening visit) PPV and will evaluate the safety and efficacy of adding PDS with ranibizumab (100 mg/ml) during vitrectomy without or with limited intraoperative PRP endolaser.
Device: PDS Implant filled with 100 mg/mL Ranibizumab · Drug: Ranibizumab
In PDR eyes with vitreous hemorrhage (VH) requiring vitrectomy, we propose to determine the safety and efficacy of adding the port delivery system (PDS) ranibizumab implant while omitting standard PRP endolaser but with the option to retain limited peripheral endolaser PRP based on surgeon discretion
The dose of ranbizumab (100mg/ml) will be identical to the FDA approved dose for treatment of nAMD and DME/DR. The schedule for refill/exchange injection will be identical to that used in the PAGODA study (q6mos refill/exchange) for DME eyes and will be identical to that used in the PAVILLION study (q9mos refill/exchange) for eyes without DME.
Proportion of Patients Without Complications of Diabetic Retinopathy at 9 Months
Proportion of patients with \<500 PRP laser spots and without the occurrence of new incidence of diabetic macular edema or diabetic retinopathy-related vitreous hemorrhage, pre-retinal hemorrhage, tractional retinal detachment or anterior segment neovascularization from Study Day 1 through Study Day 252 (Month 9).
Time frame: 9 months
Change in Vision Over 12 Months
Mean change in Best Corrected Visual Acuity (BCVA) over 12 months visual acuity
Time frame: 12 months
Need for Supplemental Treatment Over 12 Month Period
Proportion of patients needing supplemental injections, or PRP or vitrectomy over 12 months
Time frame: 12 Months
Visual FIield Changes from Month 3 to Month 12
Mean Change in Humphfrey Visual Filed Score change from postoperative month 3 to month 12
Time frame: 9 Months
Change in Retinal Nonperfusion and Leakage Over 12 Months
Change from baseline in area of retinal nonperfusion and macular leakage through 12 months, assessed with ultrawide-field fluorescein angiography by an independent reading center.
Time frame: 12 months
Number of Incidents of Ocular Adverse Events Over 12 Months
Proportion of participants with the following ocular adverse events of interest from study day 1 over 12 months: Endophthalmitis Rhegmatogenous retinal detachment (RRD) Progressed or new TRD Cataract Progression Conjunctival retraction /erosion/bleb/thickening Septum dislodgement Implant dislocation Conjunctival thickening/bleb Inability to refill/exchange due to conjunctival thickening/bleb VH secondary to PDS implant site bleeding intraoperatively Need for implant removal Need for exchange with PDS reimplantation Cataract progression requiring cataract surgery
Time frame: 12 months
Plan to share: No — The analysis population for the efficacy analyses will consist of all of the enrolled 20 eyes. Rates of primary and secondary outcomes will be compiled, analyzed and reported as a case series for publication. Analyses of primary and secondary outcomes for the subgroups of patients with and without prior PRP will be examined. Missed data will not be carried forward. Analyses at the specific time points will occur only for eyes with data at that time point.
Start is estimated for Sep 2026; primary completion for Sep 2029, 36 months later.
Of 32 phase 4 interventional studies under Diabetic Retinopathy, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's planned 36 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab
Southeast Retina Center, Georgia